Rhumbline Advisers Cardiff Oncology, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 63,142 shares of CRDF stock, worth $176,166. This represents 0.0% of its overall portfolio holdings.
Number of Shares
63,142
Previous 53,172
18.75%
Holding current value
$176,166
Previous $230,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CRDF
# of Institutions
128Shares Held
25.4MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$15 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$7.33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$6.37 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$4.29 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$4.02 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $121M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...